Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

66.29 +0.76 (+1.16%)
Streaming Delayed Price Updated: 9:44 AM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Another Tough Day For Markets
The stock market resumed its negativism today mainly linked to fear of inflation and higher interest rates, on the argument that the most dangerous thing to believe is “it's different this time.” 
Via Talk Markets
US Poised To Dispatch 20M Additional COVID-19 Shots To Countries In Need: CNBC
President Joe Biden will announce that the U.S. plans to send at least 20 million additional coronavirus vaccine doses to foreign countries still being battered by the... 
Via Benzinga
Exposures COVID-19
Medical Stocks Jazz, Horizon Are Accelerating But Iqvia Is Hitting The Brakes
Jazz Pharmaceuticals and Horizon Therapeutics are among a cadre of accelerating medical stocks, while big names like Iqvia Holdings are hitting the brakes. 
Via Investor's Business Daily
Novavax Window of Opportunity Is Closing Fast
NVAX stock is in danger of repeating prior failures. The window of opportunity is closing and it's a movie investors have seen before. 
Via InvestorPlace
Exposures COVID-19
AstraZeneca's Farxiga Flunks Late-Stage COVID-19 Study
AstraZeneca plc (NASDAQ: AZN) presented detailed data from the DARE-19 Phase 3 trial at the American College of Cardiology, evaluating Farxiga (dapagliflozin... 
Via Benzinga
Exposures COVID-19
Barron's Latest Picks And Pans: DuPont, Stanley Black & Decker, Whirlpool And More
This weekend's Barron's helps investors identify stay-at-home stocks that still have room to run. Other featured articles discuss ways investors can hedge against... 
Via Benzinga
UK Study Answers Question If Two Doses Of COVID-19 Vaccines Can Be Mix-Matched?
Preliminary data from a U.K. clinical trial testing the benefits of mixing and matching COVID-19 vaccines showed that participants who received a mixed schedule of vaccines... 
Via Benzinga
Exposures COVID-19
A Down Day
The tech wreck continues because inflation will hurt the costly stock sector more than others. 
Via Talk Markets
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
UK Rethinks COVID-19 Antibody Supply Deal With AstraZeneca: Bloomberg
The U.K. government has reconsidered its plan to buy one million doses of AstraZeneca Plc’s (NASDAQ: AZN) anti-SARS-CoV-2 antibody, according to sources... 
Via Benzinga
Exposures COVID-19
European Union Announce Second Lawsuit Against AstraZeneca Over Delayed COVID-19 Vaccine Supply: Reuters
The European Union has reportedly launched a new lawsuit against AstraZeneca plc (NASDAQ: AZN) that could lead to financial sanctions for the company,... 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Will the Blood Clot Issue Hurt AstraZeneca's Vaccine in the Long Term?
Investors should be focused on the total picture for the British pharma. 
Via The Motley Fool
Exposures COVID-19
How Will the U.S. Glut of Coronavirus Vaccines Affect Manufacturers?
The government is having issues with giving away its excess supply. 
Via The Motley Fool
Exposures COVID-19
FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic
The FDA has published a roadmap for working through the backlog of facility inspections built up during the pandemic when it postponed all routine inspections in March... 
Via Benzinga
Exposures Product Safety
FDA To Hold AdCom Meeting For Expanding Use COVID-19 Vaccine In Children
The FDA’s Center for Biologics Evaluation and Research (CBER) will convene a virtual meeting of the Vaccines and Related Biological Products Advisory Committee on June 10... 
Via Benzinga
Exposures COVID-19 Product Safety
US Support For Waiving COVID-19 Vaccine Patent Rights Puts Pressure On Drugmakers – But What Would A Waiver Actually Look Like?
The U.S. and Europe are debating waiving patent rights for COVID-19 vaccines, a move that could allow more companies to produce the vaccine around the world. But it’s not as simple as it might sound. 
Via Talk Markets
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OCTMKTS: DSNKY) have announced an update from their second antibody-drug conjugate (ADC) program... 
Via Benzinga
Biotech ETFs To Suffer As US Backs IP Waiver For COVID-19 Vaccines
The Biden administration announced support for the waiver of intellectual property protections for COVID-19 vaccines proposed by South Africa and India. Let’s take a look at ETFs that can suffer from... 
Via Talk Markets
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
Could AstraZeneca and Sanofi Win Big in RSV?
The companies have a promising RSV candidate. 
Via The Motley Fool
Calm Markets Day
Despite seriously disappointing April jobless numbers, markets are gaining all the same. 
Via Talk Markets
COVID-19 Vaccine Patent Polarizes The World: What You Need To Know
The COVID-19 pandemic is continuing to rage unabated. Just as countries across the globe were coming online from a protracted lockdown, the second and third wave of the pandemic... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
EMA Safety Committee Reviews Heart Inflammation, Rare Nerve Disorder Reports After Pfizer, AstraZeneca COVID-19 Shots
European Medical Agency (EMA) is reviewing reports of a rare nerve-degenerating disorder in people who received AstraZeneca Plc’s (NASDAQ: AZN)... 
Via Benzinga
Exposures COVID-19
AstraZeneca's Imfinzi, Tremelimumab Combo Boosts Overall Survival In Lung Cancer
A combination of AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy has extended overall survival (OS) when used as... 
Via Benzinga
Why is the EU Suing AstraZeneca?
The EU doesn't think the big drugmaker has held up its end of a supply agreement. 
Via The Motley Fool
Topics Lawsuit
Exposures COVID-19 Financial Legal
Biden Administration Backs Waiving IP Protections For COVID-19 Vaccines, Pharma Industry Rebukes Move
The closely watched issue of patent rights for COVID-19 vaccines garnered headlines again as the Biden administration came out in favor of a proposal at the World Trade... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Single Shot Of AstraZeneca, Pfizer COVID-19 Vaccines Provide 87% Protection, South Korea Study Shows: Reuters
According to real-world data released by South Korea, one dose of COVID-19 vaccines from AstraZeneca Plc (NASDAQ: AZN) and Pfizer Inc (NYSE: PFE) -... 
Via Benzinga
Exposures COVID-19
Should Pfizer and Moderna Be Worried About This New COVID Vaccine Study?
Probably not, but the study could benefit another vaccine maker. 
Via The Motley Fool
Exposures COVID-19
Facebook Sees Paid Subscribers For Workplace Rise 40% But It Remains Far Behind Microsoft's Teams
Facebook Inc (NASDAQ: FB) said Tuesday the number of paid subscribers for its enterprise communication software Workplace has jumped 40% to reach 7 million subscribers,... 
Via Benzinga
Merry Month of May
Today the unhinged markets of Monday went into normal mode as the rest of the world's markets re-opened. 
Via Talk Markets
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.